AirSculpt Technologies Reports Sales Growth Recovery Amid GLP-1 Weight-Loss Drug Trend
AirSculpt Technologies reported its first same-store sales growth in over two years, with a 1% increase in Q1. The company attributes the rebound to improved marketing and is targeting expansion tied to demand from users of GLP-1 weight-loss drugs seeking body contouring treatments for loose skin and stubborn fat.
Topics: body contouring market debt reduction GLP-1 drugs sales growth